NCT04848831 (DipA2) is a clinical trial in Invasive Pulmonary Aspergillosis, sponsored by Universitätsklinikum Hamburg-Eppendorf.

Who is sponsoring NCT04848831?

NCT04848831 is sponsored by Universitätsklinikum Hamburg-Eppendorf.

What condition does NCT04848831 study?

NCT04848831 studies Invasive Pulmonary Aspergillosis.

Is NCT04848831 still recruiting?

NCT04848831 is currently status unknown. Last updated 19 April 2021.

Last reviewed 2021-04-19 · How we verify

NCT04848831: DipA2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Diagnosis of Invasive Pulmonary Aspergillosis, Specific Testing in Bronchial Secretions Versus Bronchoalveolar Fluid

Status unknown Last updated 19 April 2021

What this trial tests

trial in Invasive Pulmonary Aspergillosis in 100 participants. Status unknown.

Timeline

1 June 2021

Primary endpoint
31 December 2022

31 December 2024

Quick facts

Lead sponsor	Universitätsklinikum Hamburg-Eppendorf
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	100
Start date	1 June 2021
Primary completion	31 December 2022
Estimated completion	31 December 2024

Conditions studied

Invasive Pulmonary Aspergillosis — all drugs for Invasive Pulmonary Aspergillosis →

Sponsor

Universitätsklinikum Hamburg-Eppendorf — full company profile →

Who can join

18 and older, any sex, with Invasive Pulmonary Aspergillosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this research project is to compare the results of Aspergillus specific test methods Aspergillus Galactomannan Enzyme Immunoassay (GM-EIA), Aspergillus polymerase chain reaction (PCR), Aspergillus Galactomannan Lateral Flow Assay (LFA) from different respiratory tract secretions. The bronchoalveolar lavage (BAL) fluid and bronchial secretions (NBL) are compared in the same examination for each patient.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

A Visual and Comprehensive Review on COVID-19-Associated Pulmonary Aspergillosis (CAPA).
Feys S, Almyroudi MP, Braspenning R, Lagrou K, et al · · 2021 · cited 67× · PMID 34947049 · DOI 10.3390/jof7121067
Comparison of the Equivalence of Aspergillus Antigen and PCR Results Between Non-Directed Bronchial Lavage and Bronchoalveolar Lavage-A Prospective Exploratory Pilot Study in Critically Ill Patients.
Schroeder M, Raboh MA, Nuechtern A, Wichmann D, et al · · 2025 · cited 1× · PMID 39900777 · DOI 10.1111/myc.70029

Verify or expand the search:

Other recruiting trials for Invasive Pulmonary Aspergillosis

Currently open trials in the same condition.

NCT07238114 — Liver Cirrhosis Patients With Invasive Pulmonary Aspergillosis: in Depth Understanding Clinical Host Risk Factors · active not recruiting
NCT06537726 — Breath Analysis for the Detection of Invasive Fungal Infections · recruiting
NCT05860387 — Early Diagnosis of Invasive Lung Aspergillosis · recruiting

Other Universitätsklinikum Hamburg-Eppendorf trials

Trials by the same sponsor.

NCT07443384 — Complications Associated With Radiofrequency Microneedling in Dermatology: a Delphi Consensus · not yet recruiting
NCT07385092 — Continuous Vital Sign Monitoring Versus Routine Spot-checks in Patients After Non-cardiac Surgery · NA · recruiting
NCT07009522 — Hamburg Emotion Awareness and Regulation Group Training for Autistic Adolescents (HEART) · EARLY_PHASE1 · not yet recruiting
NCT07115394 — EEG Measurements to Capture DBS-induced Electric Potentials · recruiting
NCT06955884 — Patient Experience of Transoral Versus Transnasal Awake Tracheal Intubation · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04848831 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Universitätsklinikum Hamburg-Eppendorf
Last refreshed: 19 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04848831.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing